CHA News Article

Report Examines Opioid Addiction Medication Access
Restrictions in Medicaid and private insurance may limit addiction treatment efforts

The American Society of Addiction Medicine (ASAM) has published new research exploring the relationship between insurance coverage – both private insurance and state Medicaid programs – and the availability of medications that treat opioid dependence. Co-sponsored by the U.S. Department of Health and Human Services, the Office of National Drug Control Policy and other federal partners, the report emphasizes that prescription medications as part of long-term treatment programs have proven effective in treating opioid addiction. However, the report also points out that, while all state Medicaid programs cover at least one FDA-approved addiction medication, restrictions vary widely from state to state, often creating disparities. Similarly, the report asserts that private insurance companies’ restrictions on opioid addiction medications can be complex and contradictory. The full report, Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment, is attached.